Novelix Pharmaceuticals Ltd
Novelix Pharmaceuticals Ltd (NOVELIX) last reported results for the quarter ended Sep 2022, with sales of ₹1.24 crore and net profit of ₹-0.15 crore. The stock last traded at ₹66.2, a market capitalisation of ₹189 crore. Over the past 52 weeks the stock has ranged between ₹38 and ₹92. Figures are as of 6 Oct 2026 and are not real time.
Novelix Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹66.2
- Market cap
- ₹189 cr
- Book value
- ₹8.89
- ROE
- -25.0%
- ROCE
- -25.7%
- Dividend yield
- 0.00%
- 52w high / low
- 92.0/38.0
Metrics as of 6 Oct 2026. Not real time.
Track Novelix Pharmaceuticals Ltd
Cruxal reads every Novelix Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Novelix Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- -1%
- 3 Years
- -6%
- TTM
- -62%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 35%
- 10 Years
- 24%
- 5 Years
- 63%
- 3 Years
- 95%
- 1 Year
- 65%
- 10 Years
- -5%
- 5 Years
- -13%
- 3 Years
- -22%
- Last Year
- -25%
Novelix Pharmaceuticals Ltd quarterly results
In the quarter ended Sep 2022, sales were ₹1.24 cr, down 49.6% from ₹2.46 cr a year earlier. Net profit swung to a loss of ₹0.15 cr.
| ₹ crore | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2.19 | 2.51 | 4.35 | 2.46 | 1.11 | 0.69 | 1.36 | 1.24 |
| Expenses | 2.44 | 5.79 | 4.52 | 2.31 | 2.08 | 2.33 | 1.5 | 1.43 |
| Operating profit | -0.25 | -3.28 | -0.17 | 0.15 | -0.97 | -1.64 | -0.14 | -0.19 |
| OPM % | -11.42% | -130.68% | -3.91% | 6.10% | -87.39% | -237.68% | -10.29% | -15.32% |
| Other income | 0.11 | 0.05 | 0.17 | 0.32 | 0.07 | 0.13 | 0.07 | 0.06 |
| Interest | 0.01 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.08 | 0.06 | 0.05 | 0.04 | 0.04 | -0.03 | 0.02 | 0.02 |
| Profit before tax | -0.23 | -3.3 | -0.05 | 0.43 | -0.94 | -1.48 | -0.09 | -0.15 |
| Tax % | 0.00% | 0.00% | 60.00% | 20.93% | -22.34% | 6.08% | 0.00% | 0.00% |
| Net profit | -0.23 | -3.29 | -0.08 | 0.35 | -0.73 | -1.57 | -0.09 | -0.15 |
| EPS (₹) | -0.26 | -4.05 | -0.19 | 0.40 | -0.77 | -1.67 | -0.09 | -0.16 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Novelix Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5.95 | 5.74 | 6.35 | 5.72 | 9.19 | 10.51 | 10.73 | 10.85 | 9.59 | 8.91 | 4.4 |
| Operating profit | 0.82 | 0.88 | 0.69 | 0.48 | 0.13 | 0.04 | 0.11 | 0.1 | -3.47 | -2.19 | -2.94 |
| OPM % | 13.78% | 15.33% | 10.87% | 8.39% | 1.41% | 0.38% | 1.03% | 0.92% | -36.18% | -24.58% | -66.82% |
| Net profit | 0.38 | 0.42 | 0.15 | 0.13 | 0.03 | -0.35 | -0.15 | -0.26 | -3.76 | -2.03 | -2.54 |
| EPS (₹) | 0.47 | 0.52 | 0.11 | 0.12 | -0.01 | -0.43 | -0.30 | -0.35 | -4.62 | -2.22 | -2.69 |
TTM is the trailing twelve months to the most recent quarter.
Novelix Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 |
| Reserves | 3.35 | 3.33 | 3.45 | 3.44 | 3.07 | 2.82 | 2.50 | -1.24 | -0.70 | -0.90 |
| Borrowings | 0.04 | 0.00 | 0.00 | 0.99 | 0.98 | 0.93 | 0.77 | 0.00 | 0.16 | 1.02 |
| Other liabilities | 0.69 | 1.08 | 1.19 | 1.22 | 1.43 | 1.49 | 2.35 | 2.72 | 1.18 | 0.23 |
| Total liabilities | 12.18 | 12.51 | 12.74 | 13.75 | 13.58 | 13.34 | 13.72 | 9.58 | 8.74 | 8.45 |
| Fixed assets | 1.17 | 0.75 | 0.70 | 2.10 | 2.17 | 1.92 | 1.83 | 1.65 | 2.20 | 2.17 |
| CWIP | 0.00 | 0.00 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 1.14 | 1.69 | 0.33 | 0.63 | 0.49 | 0.30 | 0.39 | 0.42 | 0.42 |
| Other assets | 10.96 | 10.62 | 10.09 | 11.32 | 10.78 | 10.93 | 11.59 | 7.54 | 6.12 | 5.86 |
| Total assets | 12.18 | 12.51 | 12.74 | 13.75 | 13.58 | 13.34 | 13.72 | 9.58 | 8.74 | 8.45 |
As reported by the company. Total assets equal total liabilities by construction.
Novelix Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3.45 | 0.05 | 0.30 | 2.05 | -1.82 | 0.37 | -0.53 | 0.63 | 1.59 | 1.59 |
| Cash from investing | 1.06 | 0.73 | -1.40 | -1.06 | 0.21 | -0.64 | 0.43 | 0.45 | 0.14 | -0.76 |
| Cash from financing | 2.40 | 0.17 | -0.01 | 0.22 | 0.77 | 0.02 | -0.05 | -0.16 | -0.77 | 0.00 |
| Net cash flow | 0.01 | 0.95 | -1.11 | 1.22 | -0.84 | -0.24 | -0.15 | 0.92 | 0.96 | 0.83 |
| Free cash flow | -3.58 | -0.18 | 0.20 | 1.50 | -3.11 | 0.02 | -0.38 | 0.52 | 1.56 | -0.21 |
| CFO / operating profit | -421% | 6% | 43% | 427% | -1,400% | 925% | -482% | 630% | -46% | -73% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Novelix Pharmaceuticals Ltd operating ratios
| Per year | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 5.35% | 2.39% | 2.19% | 0.88% | -0.08% | -0.80% | -0.74% | -38.23% | -25.67% |
| Debtor days | 50.30 | 54.05 | 38.51 | 33.82 | 48.85 | 75.36 | 111.92 | 44.07 | 52.52 | 50.39 |
| Inventory days | 26.47 | 27.55 | 35.78 | 40.85 | 48.28 | 42.65 | 38.29 | 43.94 | 48.42 | 43.87 |
| Days payable | 1.60 | 4.30 | 38.17 | 32.86 | 27.52 | 39.67 | 39.26 | 79.66 | 111.95 | 38.61 |
| Cash conversion cycle | 75.17 | 77.29 | 36.13 | 41.81 | 69.61 | 78.34 | 110.95 | 8.34 | -11.00 | 55.65 |
| Working capital days | 568.05 | 572.30 | 539.17 | 492.62 | 382.08 | 321.59 | 324.18 | 284.60 | 116.85 | 87.67 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Novelix Pharmaceuticals Ltd shareholding pattern
Promoters held 54.29% at Jul 2026, up from 53.33% at Sep 2025.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.56% | 66.56% | 52.75% | 53.33% | 51.97% | 49.43% | 50.57% | 54.29% |
| Public | 33.45% | 33.44% | 47.25% | 46.66% | 48.01% | 50.57% | 49.43% | 45.69% |
| No. of shareholders | 2,502 | 2,484 | 2,408 | 2,697 | 2,994 | 2,975 | 3,118 | 3,127 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Novelix Pharmaceuticals Ltd corporate filings
- Submission of Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018.Company Updatelow impact
- SEBI-regulated appointment of Mr. Gnana Prakash Gattu as Whole Time Director at Novelix Pharmaceuticals with a 5-year term, approved in 32nd AGMCompany Updatemedium impact
Cruxal's analysis: Novelix Pharmaceuticals has announced the appointment of Mr. Gnana Prakash Gattu as Whole…
Read the full analysis - Novelix Pharmaceuticals Limited's AGM results confirm strong shareholder support for key resolutions, with over 99.95% voting in favor of financial and strategic proposals, including appointment and reappointment of directors.AGM/EGMhigh impact
Cruxal's analysis: Novelix Pharmaceuticals Limited reported overwhelming approval for its resolutions at the…
Read the full analysis - Novelix Pharmaceuticals holds AGM with no immediate financial disclosures; no new financial metrics or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Novelix Pharmaceuticals Limited conducted its 32nd AGM on 30th September 2026 via video…
Read the full analysis - AttachedInsider Trading / SASTlow impact
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.